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Ether-a`-go-go1 (Eag1, Kv10.1, KCNH1) K+ channel is a member of the voltage-gated K+ channel family mainly distributed in the
central nervous system and cancer cells. Like other types of voltage-gated K+ channels, the EAG1 channels are regulated by a variety
of endogenous signals including reactive oxygen species, rendering the EAG1 to be in the redox-regulated ion channel family. The
role of EAG1 channels in tumor development and its therapeutic significance have beenwell established.Meanwhile, the importance
of hEAG1 channels in the nervous system is now increasingly appreciated. The present review will focus on the recent progress on
the channel regulation by endogenous signals and the potential functions of EAG1 channels in normal neuronal signaling as well
as neurological diseases.
1. Introduction
Ether-a`-go-go1 (Eag1), a voltage-gated K+ (Kv) channel firstly
identified in a leg shaking mutant phenotype of Drosophila
caused by spontaneously repetitive action potential firing in
motor neurons and increased transmitter release [1, 2], is
conserved in diverse mammalian species including human.
Three subfamilies of the mammalian homologs, EAG, ERG
(eag-related), andELK (eag-like), have been identified [3] and
show distinct expression patterns and electrophysiological
properties [4]. Compared to the well-known function of
human ERG1 (HERG1) channels in long QT syndrome in
cardiac arrhythmia, the physiological roles of EAG channels
remain largely unknown [5]. So far, two EAG isoforms Eag1
(KCNH1, Kv10.1) and Eag2 (KCNH5, Kv10.2) have been
identified and they show similar electrophysiological features
such as slow voltage-dependent activation, noninactivat-
ing, and inhibition by intracellular Ca2+ [Ca2+]i [4, 6, 7].
Their responses to extracellular quinidine, a broad-spectrum
K+ channel inhibitor, however, were noticeably different,
indicating this compound can be used to distinguish the
EAG channel subtypes in native cells [7]. In physiological
conditions, both EAG1 and EAG2 channels are expressed
in the brain and their distributions overlap in the cortex
and olfactory bulb, but show some differential expression
pattern in other specific locations such as thalamus [8].
The nonneural distributions of EAG1 channels are highly
constricted to a large variety of cancer cells and their roles
in cancer growth, metastasis, and the potential diagnostic
and therapeutic significance have been well established [5,
9, 10]. Likewise, EAG2 channels, although less extensively
studied, have also been revealed recently to play important
roles in medulloblastoma development and to be a potential
therapeutic target and a tumor marker [11, 12].
In humans, EAG1 is encoded by the KCNH1 gene located
on chromosome 1q32.1–32.3 [4]. Four alternative transcripts
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have been identified in the human brain and they can
translate into four different forms of proteins including the
canonical (most abundant) form, a longer variant containing
a 28-residue stretch between the transmembrane segments S3
and S4, and two shorter forms recently identified, respectively
[13].The stretch containing form shows no evident functional
differences compared to the canonical full-length standard
channel. By contrast, both shorter forms fail to form func-
tional ion channels because of lacking all transmembrane
segments but both can significantly reduce the current of
the full-length form when coexpressed in Xenopus oocytes
[13]. Like other Kv channels, the core region of EAG1
channel has six helical segments (S1 to S6), including the
voltage sensor (S1–S4) and the K+-selective pore (S5, pore
helix, and S6). Even though the overall architecture of the
EAG1 channels is similar to that of previously crystallized
Kv channel structures, there are many different aspects in
S2-S3 linker, S4, and S4-S5 linker based on the structural
models of rat EAG1 (rEAG1) channels derived by single-
particle cryoelectronmicroscopy (cryo-EM) [14].These local
structural characters may determine that EAG1 channel has
a fundamentally different voltage gating process compared
to other types Kv channels. In addition, its intracellular
domains are structurally distinct from other classical Kv
channels in that a long N-terminal region contains an eag
domain comprised of a Per-Arnt-Sim (PAS) domain and
a PAS-cap domain, while the C-terminal region contains
a cyclic nucleotide binding homology domain (CNBHD),
which is connected to the pore through a C-linker region
[15–17]. The CNBHDs of EAG1 channels share a high degree
of sequence similarity with the cyclic nucleotide binding
domain conserved in the cyclic nucleotide-gated (CNG)
channels and hyperpolarization-activated cyclic nucleotide-
modulated (HCN) channels [16]. However, CNBHD does
not bind cyclic nucleotides [17–19]. The crystal structure of
eag-CNBHD complex of mEAG channel has suggested that
the coupling between eag and CNBHD is involved in EAG
channel gating regulated by eag domain [17]. The recent
cryo-EM structure of rat EAG1 channel has further clearly
shown that the PAS domain is located at the periphery of the
intracellular region and interacts primarily with the CNBHD
from a neighboring subunit [14].The S6 helix extends into the
intracellular region and connects to theC-linker, which forms
an intracellular ring directly above the CNBHD by which the
C-linker couples the movements of the S6 and CNBHD [14].
The function of the EAG1 channels in nervous system
remained elusive until recently. A recent series of stud-
ies using gene knock-out animals and electrophysiologi-
cal recordings have provided strong evidence that EAG1
channels are important for the neuronal excitability reg-
ulation [20]. The clinical observations and genetic tests
further revealed that the gain-of-functionmutations of EAG1
channels are closely associated with two rare neuronal
developmental diseases Zimmermann-Laband and Temple-
Baraitser syndromes (ZLS and TBS) [21–24]. This article will
briefly summarize the recent progress on the mechanisms of
EAG1 channel gating regulation by endogenous molecules
and discuss its physiological and pathological functions in
nervous systems in mammals.
2. Endogenous Regulation of EAG1 Channels
The function of EAG1 channel can be regulated by a large
variety of proteins such asK+ channel regulator 1 (KCR1) [25],
CaM-dependent kinase [26], 14-3-3 protein [11], epsin [27],
rabaptin 5 [28], and cortactin [28].These proteins function as
the channel partners and affect the trafficking and expression
of EAG channels. Additionally, the channels are acutely
regulated by a large array of endogenous small molecules
including Mg2+ [29], H+ [30], H2O2 [31], arachidonic acid
(AA) [32], Ca2+ [33], phosphatidylinositol 4,5-bisphosphate
(PIP2) [34], and hormones [35–37]. The EAG channels also
undergo N-linked glycosylation before its insertion into
plasmamembrane [38]. Recent report has shown that nuclear
localization signal (NLS) can regulate the localization and
function of EAG protein [39]. The functions and potential
mechanisms of regulation by most of the aforementioned
protein factors have been reviewed recently [5]. In this review,
we will discuss the EAG channel regulation by H2O2, Ca
2+,
PIP2, glycosylation, nuclear localization signal (Figure 1),
arachidonic acid, and hormones mainly focusing on the
recent mechanistic progress.
2.1. Redox Modification. Both the expression and the func-
tion of EAG1 channels are linked to cellular oxygen home-
ostasis. Downie et al. [40] reported that EAG1-expressing
tumors showed increased angiogenesis compared to the
EAG1-negative control. EAG1 channel was proposed to inter-
fere with hypoxia homeostasis by increasing the basal HIF-
1𝛼 activity and lowering the threshold of HIF-1𝛼 activation
by hypoxia. Mild hypoxia (5% O2) induced HIF-1 expression
in EAG1-expressing cells while no increase in HIF-1 was
observed under normoxia. Sahoo et al. [31] observed that
ionic currents through the heterologously expressed EAG1
channels are progressively inhibited by intracellular applica-
tion ofH2O2, an oxidative stressmediator, possibly via attack-
ing multiple cysteine residues as revealed by a systematic
study on channel modification by specific cysteinemodifying
agents such as DTNB, MTSES+, and MTSET− combined
with cysteinemutations and electrophysiological assays.They
found that the kinetics of cysteinemodification of EAG chan-
nels contains two components; a rapid component resulted in
an alteration of gating parameters of half-activation voltage,
activation and deactivation kinetics, and the channel open
probability while the slow component caused a complete
loss of channel function. The fast component is mediated by
two cysteine residues (C145:C214) in the linker connecting
to S1, while the slower component strongly depends on two
cysteines in the C-linker region (C532:C562) connecting to
the channel gate/pore (Figure 1).
2.2. Ca2+/CaM. Intracellular Ca2+ [Ca2+]i inhibits EAG1
channels with a half-maximal inhibition at a concentration
of ∼100 nM [33] and the inhibition requires a direct binding
of CaM [41, 42]. A peptide screening combined with electro-
physiological recording has revealed three discrete sites (BD-
C1: 674–683, BD-C2: 711–721, and BD-N: 151–165) potentially
binding to Ca2+/CaM (Figure 1). Mutation of any of these
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Figure 1: Schematic representation of a KCNH1 subunit
(NM 002238.3) indicating a PIP2 binding site (blue), three CaM
binding domains (magenta), two glycosylated positions (green
balls), four oxidative modification sites (red stars), and two nuclear
localization signals (NLS) (orange).
domains can impair the inhibition of hEAG1 currents by Ca2+
[41]. Fluorescence correlation spectroscopy (FCS) affinity
assay further indicated that CaMbinding to BD-C1 is of lower
affinity as compared to the other two sites [41]. Consistently,
by visualizing the interaction between YFP-labeled CaM
and Cerulean-labeled hEAG1 in mammalian cells by Fo¨rster
resonance energy transfer (FRET),Gonc¸alves et al. [43] found
that the high affinity BD-N binding domain and the sec-
ond C-terminal binding domain BD-C2 are predominantly
involved in EAG1 channel inhibition by Ca2+. Consistently, a
recent isothermal titration calorimetry (ITC) combined with
crystal structure of the CaM-BDC2 complex study revealed
a high affinity between CaM and BD-C2 [44]. Mutations at
these two sites completely abolished CaM binding to hEAG1,
indicating that the BD-N and BD-C2 binding domains are
required for CaM binding. The recent CaM-bound cryo-EM
structuremodel of rat EAG1 channels providedmore detailed
information [14]. It is clearly shown that the channel pore
becomes smaller than the diameter of hydrated potassium
(6 to 8 A˚) when CaM is bound to the channel. The further
inspection of CaM-bound EAG1 structure showed that all
three previously identified CaM binding sites are occupied
by one CaM and four CaM molecules are bound to the
functional tetramer channel. The two contact regions in the
C terminus of CNBHD form helices that act as a claw to grab
the CaM C-lobe. The first helix (residues 683 to 695) of the
lower affinity BD-C1 domain interacts with the top of the
CaM C-lobe near the Ca2+ binding sites and the second helix
(residues 708 to 722) of the higher affinity BD-C2 domain
is bound to the hydrophobic pocket of the CaM C-lobe.
The hydrophobic core of the CaM-N-lobe binds to a helix
(residues 147 to 157) of high affinity BD-Non the PASdomain.
Based on the structure model, the authors hypothesized that
once [Ca2+]i increased, CaM may act as a molecular clamp
to pull the PAS domain and CNBHD together and then
alter the orientation of neighboring CNBHD.The orientation
alteration will lead to a rotation of both the C-linker and S6,
thereby constricting the intracellular gate and to close the
channel pore. In agreement with the structural findings, the
functional study by Lo¨rinczi et al. [45] showed that deletion
of the eag domain, CNBHD, or the C-linker abolished the
inhibitory of [Ca2+]i on EAG1 channels. All these structural
and functional findings confirmed that eag domain and
CNBHD interaction and the downstream conformational
changes in C-linker region are critical in Ca2+/CaM-induced
EAG channel gating inhibition.
2.3. PIP2. PIP2, a phospholipid composed of one negatively
charged head group and two fatty acid tails, serves as a
structural cofactor for many membrane proteins and it is
also the precursor of two important second messengers,
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3)
[46]. It is well known that PIP2 modulates a large variety of
ion channels, in which PIP2 either works as a direct channel
gate opener or as a current enhancer by facilitating the gating
process [47]. Interestingly, our previous studies have shown
that PIP2 functions as a potent inhibitory gating modifier of
the hEAG1 channel by shifting the overall voltage dependence
of activation to the positive direction [34]. Although not
accurately measured, the voltage dependence shift caused
by PIP2 may be >100mV based on the observation that a
functionally saturating concentration of PIP2 (3 𝜇M) essen-
tially eliminates the current at 40mV while the normalized
conductance without PIP2 is near unity. In addition to PIP2,
other types of phosphatidylinositol (PIs), such as PI, PI(4)P,
PI(3,4,5)P3, and PI(3,5)P2, also differentially alter the hEAG1
current, from no effect by PI to the strongest inhibition by
PI(3,5)P2, suggesting that the number of negative charges
of the head group is also critical for the channel inhibition.
By using biolayer interferometry (BLI) technique, a novel
methodology for detecting protein-protein or protein-small
molecules interactions [48], wemeasured the kinetics change
of binding between PIP2 and purified hEAG1 channel protein
and found that the kinetics of the BLI signal resembled those
observed in the patch clamp measurements in the excised
patches. In addition, the dissociation constant (𝐾𝑑) value
derived from BLI measurement is about 0.35 𝜇M, similar to
the IC50 value obtained from the electrophysiological study.
The PIP2 inhibition of hEAG1 channels is physiologically
relevant as evidenced by the observation that neuronal
transmitter 5-HT noticeably increased the whole-cell current
from the hEAG1 channels coexpressed with the serotonin
receptorHTR2A inHEK293 cells, suggesting that endogenous
PIP2 may exert a detectable tonic inhibitory influence on
hEAG1 channels in intact neurons. PIP2 also modifies other
members of EAG K+ channel family. For instance, PIP2
increases currents through hERG1 possibly via a short region
rich in positively charged residues (883RQRKRKLSFRRR894)
in the intracellular C terminus [49]. By contrast, it inhibits
hELK1 channels expressed in Xenopus oocytes by interacting
with some of the positively charged residues in the S4-
S5 linker, S6, and eag domain [50]. Amino acid sequences
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of hEAG1, hELK1, and hERG1 show considerable similarity
(∼40%) and these residues involved in PIP2 action in ERG
and ELK are not well conserved in hEAG1 channels, indi-
cating PIP2 may use different mechanisms for EAG channel
inhibition. As expected, our BLI and mutational study on
the interaction between PIP2 and themutant channels clearly
showed that PIP2 binding required a short segment located in
the downstream of the EAG domain close to S1 (Figure 1), a
short region called CaM-N identified previously because of
the potential Ca2+/CaM binding [41]. Although lacking more
detailed information, our results suggested that, similar to
the approach by which Ca2+/CaM inhibits EAG1 channels
[45], PIP2 may alter the voltage dependence of activation
by changing the physical coupling between eag domain and
CNBHD [14, 17].
2.4. Glycosylation. N-linked glycosylation is a common post-
translational modification of membrane proteins including
many types of ion channels. The changes in the glycosylation
pattern may affect the surface charge, which could then
cause abnormal trafficking and dysfunction of ion channel,
leading to neurological disorders [51]. Although N-linked
glycosylation is very common, some types of ion channels
such as Kv1.6 and Kv2.1 are glycosylation deficient [52]. Napp
et al. [38] found that expression of Eag1 in glycosylation
deficient Lec1 cells or tunicamycin-treatedCHOcells induced
the localization of Eag1 to unidentified perinuclear structures,
suggesting the correct glycosylation is necessary for both
Eag1 channel trafficking to the plasma membrane and the
proper function. The glycosylation sites of EAG channels
include Asn-388 and Phe-405, two residues located in the
extracellular loop between the S5 and S6 transmembrane
domains (Figure 1). But they show noticeable differences in
the glycosylation pattern; Asn-388 seems to undergo only
core glycosylation, but more complex sugars are bound to
Phe-405, shifting the apparent molecular mass of single
subunit of EAG1 channel from 100 to 110 and 130 kDa,
respectively, as assessed by Western blot analysis. Besides the
correct channel folding, trafficking, expression, and normal
function of EAG channels, the other distinct physiological
significance of glycosylation may relate to the channel’s lower
sensitivity to some toxins, which display potent inhibition
on other types of Kv channels. The recent cryo-EM structure
model of rEAG1 channel has clearly shown that EAG1 channel
has an extended extracellular turret, a distinct structural
character compared to all previously identified Kv channel
structures [14, 53].The sugar chains on the glycosylation sites
in the turret can prevent the binding of the toxins to the
channel pore.
2.5. Nuclear Localization Signal. The classical nuclear local-
ization signal (NLS) facilitates the trafficking of a cellular pro-
tein into the cell nucleus for precise regulation of the cellular
process such as gene expression [54], cell cycle, and signal
transduction [55]. Since the first NLS identified in SV40 large
T-antigen [56], many proteins including ion channel proteins
have been found to carry one or multiple NLSs [39, 57–
59]. The identification of the functional NLSs in ion channel
proteins would provide novel roles besides the traditional
ion permeation function. For instance, the NLS in the C.
elegans TRPV channel OCR-2 facilitates the accumulation
of a synthetic cargo protein and the C-terminal cytosolic
fragment of OCR-2 [57]. The NLSs of the intracellular anion
channel protein 4 (CICL4) can mediate the channel itself to
enter into the nucleus in response to cellular stress [58] and
the NLS of 𝛾-subunit of the epithelial Na+ channel (ENaC)
could regulate the channel activity in a feedbackmanner [59].
Interestingly, Sun et al. also found two NLSs in the carboxy-
terminal of Drosophila Eag80, an 80 kDa EAG splice variant
containing both N- and C-terminal sequences but lacking all
channel-forming transmembrane domains [39]. The Eag80
C-terminal contains two putative nuclear localization signals
NLS1 and NLS2 (Figure 1), one putative nuclear export signal
(NES), and binding domains forCaMandCaMKII. Although
it does not produce an active ion channel, Eag80 activates
a signaling cascade leading to altered cell architecture and
NLS1 has been demonstrated to be necessary for such cell
morphology alteration. Although the exact mechanism by
which the splice variant carrying NLSs of EAG channel
protein change cell structure still needs to be uncovered,
the established relationship between morphologic changes
of neuron cells and aging as well as sporadic Alzheimer’s
disease is likely linked to the regulatory role of these cell shape
remodeling related splices on the neural circuit associated
with neurodegenerative diseases [60]. Apparently, the Eag80
is distinct from the inner nuclear membrane located EAG
channel because the latter’s nuclear localization does not
require the NLS and it shows electrical properties compatible
with full-length EAG1 channels [61]. Recently, two mam-
malian orthologs of the Eag80 splice variants in Drosophila
have been identified in multiple tumor cells and brain tissue
[13]. They are E65 and E70 with the predicted protein size
of 65 and 70 kDa, respectively. Similar to EAG80, both
variants completely lack the transmembrane domains and
produced cytoplasmic proteinswithout any channel function.
Coimmunoprecipitation assay shows that both E65 and E70
interact with the full-length EAG1 channel and can down-
regulate EAG1 current when they are coexpressed with the
full-length form [13]. Surprisingly, their mechanisms for the
full-length EAG channel current regulation are different. E65
causes an overall reduction in KV10.1 protein level and also
reduces single channel current, whereas E70 mainly affected
the glycosylation pattern but without detectably affecting the
electrophysiological parameters [13].The interaction between
the full-length EAG1 channel and the splice variants does not
rely on the C-terminal tetramerization domain. However, the
interaction between the short isoforms and the full-length
channel would occur through other unknown interaction
sites. Unfortunately, none of these splice variants could be
detected as protein in native systems. Thus, more studies are
required before understanding their physiological functions
of these NLS contained splice variants.
2.6. Arachidonic Acid. Arachidonic acid (AA), a long-chain
polyunsaturated fatty acid, serves as a major constitute of
cell membrane of neuronal tissues [62, 63] and can be
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released as a second messenger during neurotransmission
[64, 65]. Maintaining a sufficient level of AA is a key issue
for the neurological health. AA deficiency is associated with
many neuronal diseases such as Alzheimer disease [66],
bipolar disorder [67], epileptic seizures, and depression [68].
Accumulating evidence suggests that the effects of AA are
mediated by regulation of some types of ion channels [69].
In the nervous system, AA and its metabolites can modulate
activities of multiple ion channels directly or indirectly,
including tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-
resistant (TTX-R) sodium channels [70], voltage-gated Ca2+
and K+ channels [71–73], Ca2+-dependent K+ channels [74],
and acid-sensing ion channels [75]. HEAG, as one of the
voltage dependence K+ channels responsible for controlling
neuronal excitability in the nervous system, has been identi-
fied as another AA-sensitive ion channel by Gavrilova-Ruch
et al. [32].They reported thatAAcan enhance hEAGchannels
activity by shifting the voltage dependence of activation to the
negative voltage, resulting in enhanced humanmelanoma cell
proliferation. The previous studies have suggested that AA
may directly bind to the channel pore [76, 77], N-terminal
[78], or C-terminal sites [79]. The evidence from the kinetic
changes of EAG1 channels by AA has suggested that AA
directly interacts with the EAG1 channel. Besides EAG1, AA
also activates EAG2 and ERG1 channels, implicating a con-
servedmechanism involved in AA-mediated activation of the
EAG channel family [32, 80]. The neurological significance
of EAG1 regulation by AA is not yet known; however, based
on the wide distributions of AA and EAG1 in the nervous
system, it is reasonable to expect that modulation of EAG1
by AA could play important roles in neuronal signaling and
excitability.
2.7. Estrogen and Progesterone. Both estrogen and proges-
terone display protective effects against some neurodegener-
ative disorders including stroke, traumatic brain injury [81–
83], Parkinson’s disease [84, 85], and other neurodegenerative
diseases [86, 87]. Like other steroids, the effects of estrogen
and progesterone are thought to be dependent on their
genomic effect via activation of their nuclear receptors [88,
89]. However, the nongenomic effect of both hormones
has been appreciated and, at least in part, is dependent on
their direct regulation of select ion channels. For example,
progesterone at micromolar concentrations directly blocks
the voltage-dependent calcium channel that triggers neu-
rotransmitter release to alleviate the neurotoxicity in the
brain [90] and the therapeutic concentrations can block
the voltage-gated potassium channel in striatal neurons in
rats [89]. Similarly, estrogen can exert rapid regulation of
potassium and calcium channels in neurons by activation
of estrogen receptors to regulate the neuronal activities [88]
and inhibit the epileptiform bursting activities in cultured
hippocampal neurons by activation of the voltage-gated
potassium channel Kv4.2 [91]. Estrogen and progesterone
have been reported to upregulate the expression of EAG
channel proteins in cervical cancer cells and normal cervical
cells [35–37]. The identifications of EAG as estrogen- and
progesterone-responsive ion channel give a strong hint that
EAG1 channels would be involved in the hormone induced
signal pathways. Undoubtedly, future studies are needed to
determine if native neuronal EAG channels can bemodulated
by these two hormones and what roles, if any, they may
have in mediating physiological functions of EAG channels
in CNS.
3. Functions of EAG1 Channels in Normal
Neuronal Signaling
The functional contribution of EAG channel to excitability
regulation in Drosophila has been extensively studied and
well accepted in the field [1, 92–94]. In zebrafish, Stengel
et al. found that EAG1 is crucial for the early embryonic
development and patterning [95]. In mouse, the present
evidence from EAG1 knock-out experiment has shown that
EAG1 deficiency does not significantly alter the embryoge-
nesis, development, social behavior, learning and memory,
and themajor electrical properties of cerebellar Purkinje cells.
The deficiency of EAG1 only caused a mild hyperactivity
and longer-lasting haloperidol-induced catalepsy but did not
affect amphetamine sensitization and withdrawal and the
reactivity to apomorphine and haloperidol in the prepulse
inhibition (PPI) tests or to antidepressants in the haloperidol-
induced catalepsy [96]. Consistently, Issy et al. [97] also found
that injection of anti-EAG1 antibody into the dentate gyrus
of hippocampus did not modify apomorphine-disruptive
effects in the PPI response. However, it is noteworthy that
the EAG1 antibody completely restored the startle amplitude
decrease revealed after dentate gyrus surgery. More in-
depth inspection on the EAG1-deficient mice using patch
clamp and two-photon Ca2+ imaging by Mortensen et al.
[20] demonstrated that EAG1 is enriched in the presynaptic
terminals and is not involved in the somatic action potentials
(APs) in the cerebellum. However, they found that the EAG1
channel regulates Ca2+ influx and neurotransmitter release
during repetitive high-frequency activity. For example, the
authors noticed that Ca2+ influx into axonal boutons was
enhanced in mutant mice in response to the stimulation
with three APs, but not to a single AP. This stimulation
frequency-dependent Ca2+ release indicates that the EAG1
channel plays a fine-tuning role in synaptic transmission
during high-frequency firing when other potassium channels
suffer cumulative inactivation [20]. In addition, the presence
of EAG1 channels in the nigrostriatal pathway in the rat brain
indicates that EAG1 channels may be involved in Parkinson’s
disease characterized by partial or complete loss of dopamin-
ergic neurons [98].The observations by Ferreira et al. showed
that both EAG1 channel and tyrosine hydroxylase immunore-
activity decreased in ipsilateral striatum in the neurotoxin
6-hydroxydopamine (6-OHDA) injected rats [98]. On the
basis that the reactive oxygen species (ROS), such as the
superoxide anion and H2O2, mediate the cytotoxicity of
dopaminergic neurons by 6-OHDA [99] and EAG1 channels
are greatly sensitive to H2O2 modification [31], it will be
worth exploring the physiological roles of EAG1 channels
in dopaminergic midbrain neurons as well as in Parkinson’s
disease.
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Figure 2: Schematic presentation of KCNH1 channel subunit (NM 172362.2) and the location of all identified mutations associated with TBS
(red balls), ZLS (blue balls), and undefined neurodevelopmental disorders (brown balls).The amount of “+” indicates the number of patients
with a certain type of mutations, and the color of “+” corresponds to patients with a certain type of disorders.
4. EAG1 Channel Dysfunction in Genetic
Neurological Disease
With the advance in the genome sequencing, the pathological
functions of EAG1 channels in the nervous system are
beginning to be revealed. A series of clinical observations
have shown that gain-of-function of EAG1 gene mutations
is strongly associated with two severe neurological and
developmental disorders, Zimmermann-Laband syndrome
(ZLS) [21, 22] and Temple-Baraitser syndrome (TBS) [23,
100].The EAG1mutations were also found in some undefined
syndromes with intellectual disability and overlapping char-
acters of ZLS and TBS [24, 50], which greatly increases the
appreciation about the importance of physiological function
of EAG1 channels. Here, we will review the recent litera-
tures [21–24, 50, 100] and summarize the advances in the
understanding of EAG1 channel mutations in the etiology of
ZLS/TBS.
4.1. The Relationship between the Gain-of-Function of EAG1
Mutations and Phenotypes of ZLS/TBS. Although sharing
some similar syndromes, TBS and ZLS patients show dis-
tinct features: the former is characterized by intellectual
disability, epilepsy, and hypoplasia or aplasia of the nails
of the thumb and great toes [101, 102], and the latter is
characterized by gingival enlargement, intellectual disability,
hypoplasia or absence of all nails and terminal phalanges, and
hypertrichosis and associated with or without epilepsy [103–
105], respectively. Using whole-exome sequencing (WES)
technique, Simons et al. [23] and Kortu¨m et al. [21] almost
simultaneously connected the genetic causes of ZLS and
TBS to EAG1 channel gain-of-mutations. So far, a total
of twenty-two cases with pathogenic EAG1 mutations have
been reported in all six published papers [21–24, 50, 100].
Twelve different gain-of-function EAG1 mutations have been
identified in twenty-two patients, in which five mutations are
TBS-associated [23, 100], six mutations are ZLS-associated
[21, 22], and four mutations are associated with atypical
syndromes of ZLS/TBS as shown in Table 1 [24, 50]. However,
no loss-of-function mutation was identified (Figure 2). Inter-
estingly, three mutations including Ile494Val, Gly375Arg,
and Leu489Phe were found to be associated with both
ZLS/TBS and the patients with atypical syndromes [23,
50], suggesting a crossed genotype-phenotype correlation.
Such a correlation is theoretically possible based on the
fact that the specific clinical characteristics of ZLS and TBS
have not been clearly classified yet, which will definitely
make it difficult to diagnose the patients as TBS or ZLS.
Generally, one can distinguish TBS from ZLS according to
their characteristic phenotypes displaying the nail hypoplasia
or aplasia only on the great toes and thumbs in TBS but
all nails dysplasia in ZLS [101, 102, 106, 107]. But not all the
patients always present these distinct phenotypes even when
associated with the same EAG1 mutation such as Leu489Phe
[23, 50]. In fact, some common clinical features including
intellectual disability, epilepsy, deafness, and seizures can be
noted among these neurodevelopmental disorders, showing
the overlapping phenotypes [100].
Both Ile494Val and Gly375Arg mutations were detected
in patients with ZLS and TBS [21–23, 100], providing the
stronger evidence that these two syndromes belong to a phe-
notypic continuum.However, the careful clinical comparison
has found that the patients carrying the same mutations still
show various phenotypes. For instance, both the patient # 3
with ZLS (19 years old) in Kortu¨m et al.’s study [21] and that
with TBS (9 months old) in Me´garbane´ et al.’s study [100]
carried Gly375Arg mutation, but the seizures only occurred
in patient # 3 with ZLS [21, 100]. On the other hand, even
though we hypothesized that the EAG1 mutation is the major
cause of ZLS/TBS, other factors could also play a tuning role
in shaping the distinct phenotypes. It is worth mentioning
that patient # 2 with ZLS from Kortu¨m et al. [21] carrying
two mutations in cis displays nail aplasia of three toes which
means the patient showed a more severe limb abnormality
than other ZLS patients with only one site mutation [21]. It
seems that a single point KCNH1 mutation is not enough
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Table 1: Demographic, genetic, and clinical data in all reported subjects with KCNH1 mutations.
Mutations Reference TBS ZLS Atypical
615G>C
Lys217Asn
Patient D
Simons et al., 2015 + − −
974C>A
Ser325Tyr (Ser352Tyr)
1066G>C
Val356Leu (Val383Leu)
Patient 2
Kortu¨m et al., 2015 − + −
1070G>A
Arg357Gln
Patient 1
Bramswig et al., 2015 − − +
Patient 2
Bramswig et al., 2015 − − +
Patient 3
Bramswig et al., 2015 − − +
Patient 1
Fukai et al., 2016 − − +
Patient 2
Fukai et al., 2016 − − +
1070G>C
Arg357Pro
Patient 3
Fukai et al., 2016 − − +
1042G>A
Gly348Arg (Gly375Arg)
Patient 3
Kortu¨m et al., 2015 − + −
Patient
Me´garbane´ et al., 2016 + − −
Patient
Mastrangelo et al.,
2016
− + −
1054C>G
Leu352Val (Leu379Val)
Patient 5
Kortu¨m et al., 2015 − + −
1465C>T
Leu489Phe
Patient B
Simons et al., 2015 + − −
Patient 4
Bramswig et al., 2015 − − +
1480A>G
Ile494Val
Patient C
Simons et al., 2015 + − −
Patient E
Simons et al., 2015 + − −
Patient F
Simons et al., 2015 + − −
Patient 1
Kortu¨m et al., 2015 − + −
Patient 6
Kortu¨m et al., 2015 − + −
1405G>A
Gly469Arg (Gly496Arg)
Patient 4
Kortu¨m et al., 2015 − + −
1487G>A
Gly496Glu
Patient 4
Fukai et al., 2016 − − +
1508A>G
Gln503Arg
Patient A
Simons et al., 2015 + − −
Total 12/22 22 7 7 8
+: present; −: absent; TBS: Temple-Baraitser syndrome; ZLS: Zimmermann-Laband syndrome; atypical: undefined neurodevelopmental disorder. The
mutations in brackets represent the translatedmutations that are originally found in short KCNH1 isoform (NM 002238.3) and in long isoform (NM 172362.2)
for the easier comparison.
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to cause the distinguishable phenotypic clinical features for
all patients. Hence, genetic mutation accumulation may
contribute the serious phenotypic syndromes.
4.2. Is the Hotspot Mutation Indicated? Identification of a
hotspotmutationwould simplify the clinical diagnosis for the
prospective patients, offering a possibility of understanding
the etiology of these neuronal disorders and even to find a
potential treatment. However, more than half of the patients
with the typical and atypical ZLS/TBS syndromes carry
different mutations as shown in Table 1. Moreover, even the
rest of the patients with the same genetic mutation clearly
show different clinical phenotypes. Although Arg357 and
Ile494 mutations have been identified in six and five different
patients in ZLS and TBS, suggesting these two mutations
maybe high frequently occurred and can be recognized as the
hotspot mutations in ZLS and TBS, respectively, it still needs
further clinical and genetic confirmation given a very small
number of patients in the studies and the diverse phenotypes
of patients carrying the same mutation [21, 23].
4.3. Functional Research of Gain-of-Mutation of EAG1 Chan-
nel and the Potential Correlation with Epilepsies. K+ channels
are a major negative regulator of membrane excitability and
impairment of K+ channel function by genetic mutations
has been involved in multiple human epileptic [108, 109].
Although the causality between the cellular excitability and
epilepsy is not demonstrated yet, the channel blockers of
voltage-gated Na+ and Ca2+ channels, and channel activators
of GABA receptors are therapeutically effective in a large
amount of patients with epilepsy [22]. The epileptic syn-
drome, a very common character of ZLS/TBS patients, how-
ever, was found to be associated with the gain-of-function
of EAG1 mutation. The electrophysiological function of the
gain-of-function mutatuion of EAG1 channel has been tested
in a heterologous expression system [21, 23]. The mutant
channels displayed no apparent difference in the current
amplitude compared to wild-type channels, but most of
the mutants exhibited an accelerated activation and slower
deactivation kinetics. The apparent threshold of voltage-
dependent activation is also more negative than that of
wild-type channels [21, 23]. The overall electrophysiological
property changes indicate that the gain-of-functionmutation
would result in an enhanced K+ transporting function,
which prefers to maintain a more negative resting membrane
potential thereby limiting the opening of voltage-gated Na+
and Ca2+ channels, two major effectors during epilepsy [21].
This EAG1 mutation with gain-of-function compared to that
in other K+ channels with loss-of-function indicates that
the mechanisms mediating the epilepsy may be different
from that in classical types of epilepsy [109], although some
sodium channel blockers and GABA receptor agonists such
as rufinamide, topiramate, and nitrazepam have been used
to control seizures on the KCNH1 mutation-affected cases
[22]. Interestingly, it has been noted that some gain-of-
function mutations of K+ channels are also implicated in
human epilepsies [110]. The following studies by Shruti et al.
have indicated that the elevated firing activity in neocortical
pyramidal neurons is a potential mechanism of epileptic
patients associated with a gain-of-function mutation of the
large conductance and Ca2+ activated K+ (BK) channel [111].
How the gain-of-function of EAG1 mutant channel leads
to epilepsies remains elusive. Given both types of channels
mainly expressed in presynaptic membrane of neurons [20,
111], the gain-of-functionmutation of BK and EAG1 channels
may share common mechanisms in epilepsy generation.
Thus, in addition to the electrophysiological properties of
the gain-of-function of EAG1 mutant channels on heterol-
ogous models, further investigating whether the mutant
EAG1 channels change the overall electrical properties of the
neurons in situ and in vivo models will be critical to elucidate
the mechanisms of epilepsy associated with EAG1 channel
mutation.
4.4. Potential Mechanisms of Gain-of-Function Mutation of
EAG1 Channels. The specific mechanism by which these
mutations change the gating behavior is not clear. The recent
cryo-EM structural model of rEAG1 channel may provide
some clues. The cryo-EM structure of rEAG1 channel has
revealed that the S4 segment directly interacts with C-linker
to induce a bent in S6 segment to close the channel under a
hyperpolarized state and the bendwill come back without the
interaction with S4 to open the channel under a depolarized
conformation [14]. Therefore, any changes on these helices
would perturb their movements, destabilize the closed state,
and affect the biophysical properties of EAG1 channels. To
understand the potential mechanisms, the localization of all
12 mutations was indicated in Figure 2. which shows that
some of the mutation sites are located in the S4, S6, or
C-linker domains important for EAG1 channel activation.
The mutation in these domains could perturb movement
of these domains and the subsequent interaction, favor-
ing the opening state. In addition, the cryo-EM structural
model of rEAG1 has shown that S4-S5 linker can direct
the cytoplasmic C-terminal end of S4 to move toward the
C-linker by interacting with the C terminus of S6 under
the channel open state. The spatial orientation and proper
distance between the C terminus of S4 and the C-linker are
necessary for their interaction when the voltage sensors are
in the hyperpolarized state. Hence, Gly375Arg mutation is
likely to obstruct the S4-S5 linker motion to the direction of
C terminus of S4, which could influence the proper channel
gating. Moreover, the S4-S5 linker can be an integrator of the
N terminus of the PAS domain to modulate the activation
kinetics of EAG1.Thus, any amino acidmutation in the linker
could affect the movement of neighboring N terminus of PAS
or the whole PAS domain thereby changing the activation
kinetics of EAG1 channel. The mutation in the S4-S5 linker
could also interrupt its interactionwith theN terminus of PAS
and may have an impact on the channel’s activation kinetics,
shifting of the gating equilibrium of EAG1 mutant channels
to the open state. All these hypotheses will give insights into
the molecular mechanism by which the mutations in these
domains may have a gain-of-function. A recent report has
shown that Arg327 mutation in EAG2 channel promotes the
channel constitutively opening by reducing the interaction
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with other negatively charged residues [112]. The cryo-EM
structure has suggested that a region formed by F261 and
D264 from S2 and D299 from S3 can facilitate the traverse
of arginine residues in S4 when the charge transfer center
is moving outward with depolarization. Mutation Arg357, a
residue located below the voltage sensors in S4, may impede
the backward movement of voltage sensor from the activated
state. The more detailed molecular mechanisms of the gating
of the mutant EAG1 channels need further investigation.
5. Conclusion and Perspective
The fine-tuning effect of EAG1 on synaptic transmission in
transgenic mice models may suggest that more in-depth
investigation of differential phenotypes from the cellular
to in vivo level is necessary. Indeed, besides the plasma
membrane, EAG1 channel has also been reported to be
present in the inner membrane of the nuclear, indicating the
channel may play some unexpected roles in gene regulation.
In addition, although multiple gain-of-function mutations of
EAG1 channels have been implicated in the developmental
neurological disorders including epilepsy, more mechanistic
studies are badly needed to build a causality connection
between the genetic changes of EAG1 and clinical phenotypes
of neuronal disorders. All these efforts will greatly improve
our understanding of physiological and pathological signifi-
cance of EAG1 channels.
The gain-of-function mutation of EAG1 channels in
ZLS/TBS and the aberrant overexpression of channels in
cancer cells have strongly suggested that targeting EAG1
channels is ideal diagnostic and therapeutic strategies for
both EAG1-associated neuronal and nonneuronal diseases.
Unfortunately, no specific EAG1 channel blockers are avail-
able. The crystal structure of eag-CNBHD complex provides
a promising approach for generating specific drugs target-
ing eag-CNBHD complex, the most distinct part of EAG1
channel compared to other Kv channels. However, pursuing
for a specific EAG1 channel gating inhibitor by targeting the
eag-CNBHD complex failed to find any high affinity leads
[113]. The recent cryo-EM structural model of full-length
EAG1 channel will facilitate the specific inhibitor discovery
process. In addition, the research on endogenous regulations
and the involved mechanisms will also be contributable.
For instance, intracellular Ca2+/CaM and PIP2/3 have been
shown strong inhibition on EAG1 channel gating. But the
physiological significance caused by these gate inhibitors
is largely unknown. The recent research has revealed that
the dynamics of membrane phospholipids is regulated by
membrane potential and intracellular local Ca2+ [112, 114],
indicating that the EAG1 channels are located in a more
complicated environment in which any changes in PIP2/3,
Ca2+/CaM, or membrane potential may eventually change
the EAG1 channel function. Understanding such a compli-
cated regulation network will be helpful to further reveal
the functions of EAG1 channels in both physiological and
pathological conditions.
The findings that EAG1 channels are expressed in
dopaminergic neurons strongly suggest that the channel may
function in Parkinson’s diseases and other types of neu-
rodegenerative diseases in which the oxidative damage plays
important roles. Moreover, the elucidation of mammalian
EAG1 channel structure and the potential mechanisms for
channel regulation by a variety of endogenous factors widely
expressed in our body including nervous systems will defi-
nitely provide valuable information for EAG1 channel drug
development.
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